Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
DRUG

AMG 181

Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

OTHER

Placebo for AMG 181

Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

Trial Locations (8)

3004

Research Site, Prahran

4006

Research Site, Herston

5000

Research Site, Adelaide

16635

Research Site, Duncansville

33143

Research Site, Miami

91206

Research Site, Glendale

06606

Research Site, Bridgeport

06810

Research Site, Danbury

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY